S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.33 (+0.04%)
AAPL   189.82 (+0.02%)
MSFT   381.35 (+0.72%)
META   336.68 (+0.59%)
GOOGL   136.64 (+0.17%)
AMZN   146.74 (-0.67%)
TSLA   245.71 (+4.08%)
NVDA   476.34 (-1.26%)
NIO   7.25 (+0.83%)
BABA   76.45 (-1.39%)
AMD   121.55 (-0.90%)
T   16.11 (-0.62%)
F   10.36 (+0.19%)
MU   75.32 (-2.83%)
CGC   0.54 (-2.23%)
GE   118.77 (-1.00%)
DIS   92.90 (-2.39%)
AMC   6.67 (-1.91%)
PFE   29.67 (-1.56%)
PYPL   58.58 (+3.88%)
XOM   104.21 (+0.24%)
S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.33 (+0.04%)
AAPL   189.82 (+0.02%)
MSFT   381.35 (+0.72%)
META   336.68 (+0.59%)
GOOGL   136.64 (+0.17%)
AMZN   146.74 (-0.67%)
TSLA   245.71 (+4.08%)
NVDA   476.34 (-1.26%)
NIO   7.25 (+0.83%)
BABA   76.45 (-1.39%)
AMD   121.55 (-0.90%)
T   16.11 (-0.62%)
F   10.36 (+0.19%)
MU   75.32 (-2.83%)
CGC   0.54 (-2.23%)
GE   118.77 (-1.00%)
DIS   92.90 (-2.39%)
AMC   6.67 (-1.91%)
PFE   29.67 (-1.56%)
PYPL   58.58 (+3.88%)
XOM   104.21 (+0.24%)
S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.33 (+0.04%)
AAPL   189.82 (+0.02%)
MSFT   381.35 (+0.72%)
META   336.68 (+0.59%)
GOOGL   136.64 (+0.17%)
AMZN   146.74 (-0.67%)
TSLA   245.71 (+4.08%)
NVDA   476.34 (-1.26%)
NIO   7.25 (+0.83%)
BABA   76.45 (-1.39%)
AMD   121.55 (-0.90%)
T   16.11 (-0.62%)
F   10.36 (+0.19%)
MU   75.32 (-2.83%)
CGC   0.54 (-2.23%)
GE   118.77 (-1.00%)
DIS   92.90 (-2.39%)
AMC   6.67 (-1.91%)
PFE   29.67 (-1.56%)
PYPL   58.58 (+3.88%)
XOM   104.21 (+0.24%)
S&P 500   4,548.14 (-0.05%)
DOW   35,402.02 (+0.19%)
QQQ   389.33 (+0.04%)
AAPL   189.82 (+0.02%)
MSFT   381.35 (+0.72%)
META   336.68 (+0.59%)
GOOGL   136.64 (+0.17%)
AMZN   146.74 (-0.67%)
TSLA   245.71 (+4.08%)
NVDA   476.34 (-1.26%)
NIO   7.25 (+0.83%)
BABA   76.45 (-1.39%)
AMD   121.55 (-0.90%)
T   16.11 (-0.62%)
F   10.36 (+0.19%)
MU   75.32 (-2.83%)
CGC   0.54 (-2.23%)
GE   118.77 (-1.00%)
DIS   92.90 (-2.39%)
AMC   6.67 (-1.91%)
PFE   29.67 (-1.56%)
PYPL   58.58 (+3.88%)
XOM   104.21 (+0.24%)

Supernus Pharmaceuticals (SUPN) Competitors

$27.18
+0.09 (+0.33%)
(As of 03:10 PM ET)
Compare
Today's Range
$26.94
$27.96
50-Day Range
$22.72
$29.21
52-Week Range
$21.99
$42.09
Volume
105,995 shs
Average Volume
434,475 shs
Market Capitalization
$1.48 billion
P/E Ratio
66.29
Dividend Yield
N/A
Price Target
$43.00

SUPN vs. PCRX, CORT, CPRX, IRWD, PNT, SMMT, RYZB, AMRX, MRUS, and TARO

Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Catalyst Pharmaceuticals (CPRX), Ironwood Pharmaceuticals (IRWD), POINT Biopharma Global (PNT), Summit Therapeutics (SMMT), RayzeBio (RYZB), Amneal Pharmaceuticals (AMRX), Merus (MRUS), and Taro Pharmaceutical Industries (TARO). These companies are all part of the "pharmaceutical preparations" industry.

Supernus Pharmaceuticals vs.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, community ranking, dividends, profitability and institutional ownership.

Supernus Pharmaceuticals currently has a consensus price target of $43.00, suggesting a potential upside of 57.86%. Pacira BioSciences has a consensus price target of $52.36, suggesting a potential upside of 92.02%. Given Pacira BioSciences' higher possible upside, analysts clearly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Pacira BioSciences
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Supernus Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Supernus Pharmaceuticals has a net margin of 4.20% compared to Pacira BioSciences' net margin of 1.05%. Pacira BioSciences' return on equity of 12.16% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals4.20% 2.82% 1.69%
Pacira BioSciences 1.05%12.16%6.16%

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 2 articles in the media. Pacira BioSciences' average media sentiment score of 0.93 beat Supernus Pharmaceuticals' score of 0.77 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pacira BioSciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Supernus Pharmaceuticals has higher revenue and earnings than Pacira BioSciences. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$667.24M2.23$60.71M$0.4166.29
Pacira BioSciences$666.82M1.92$15.91M$0.09305.56

99.7% of Pacira BioSciences shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by company insiders. Comparatively, 6.6% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Pacira BioSciences received 330 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.17% of users gave Supernus Pharmaceuticals an outperform vote while only 71.59% of users gave Pacira BioSciences an outperform vote.

CompanyUnderperformOutperform
Supernus PharmaceuticalsOutperform Votes
469
73.17%
Underperform Votes
172
26.83%
Pacira BioSciencesOutperform Votes
799
71.59%
Underperform Votes
317
28.41%

Summary

Supernus Pharmaceuticals beats Pacira BioSciences on 9 of the 17 factors compared between the two stocks.


Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUPN vs. The Competition

MetricSupernus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.48B$5.80B$4.48B$6.67B
Dividend YieldN/A3.13%2.96%6.96%
P/E Ratio66.297.62100.5911.59
Price / Sales2.23144.202,539.9057.91
Price / Cash9.9215.3121.6322.84
Price / Book1.663.883.794.46
Net Income$60.71M$197.64M$121.50M$175.69M
7 Day Performance-0.18%5.11%2.88%2.14%
1 Month Performance15.37%9.37%13.32%9.43%
1 Year Performance-23.65%3.40%4.69%2.37%

Supernus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PCRX
Pacira BioSciences
2.8928 of 5 stars
$26.66
-3.7%
$52.36
+96.4%
-46.9%$1.24B$666.82M296.22715
CORT
Corcept Therapeutics
2.5414 of 5 stars
$25.42
-2.0%
$32.19
+26.6%
-3.2%$2.62B$450.03M31.38299Short Interest ↑
Positive News
CPRX
Catalyst Pharmaceuticals
2.7412 of 5 stars
$13.74
+0.2%
$24.75
+80.1%
-16.9%$1.46B$348.39M26.4282Positive News
IRWD
Ironwood Pharmaceuticals
2.1082 of 5 stars
$9.37
-1.5%
$20.67
+120.6%
-18.2%$1.46B$432.38M-1.50219
PNT
POINT Biopharma Global
1.7789 of 5 stars
$13.71
flat
$13.10
-4.4%
+106.0%$1.46B$243.69M15.23129Options Volume
SMMT
Summit Therapeutics
1.6548 of 5 stars
$1.98
-0.5%
N/A+117.8%$1.39B$700,000.00-1.2876
RYZB
RayzeBio
2.307 of 5 stars
$23.08
-0.9%
$31.33
+35.8%
N/A$1.38BN/A0.0088Negative News
AMRX
Amneal Pharmaceuticals
2.0322 of 5 stars
$4.47
-0.4%
$4.80
+7.4%
+79.7%$1.37B$2.39B74.507,600Short Interest ↑
News Coverage
Positive News
MRUS
Merus
1.6407 of 5 stars
$23.66
-2.6%
$44.90
+89.8%
+52.4%$1.37B$41.59M-6.29164Analyst Report
News Coverage
TARO
Taro Pharmaceutical Industries
1.5772 of 5 stars
$36.46
+1.8%
$35.00
-4.0%
+23.3%$1.35B$592.89M41.911,554Short Interest ↓

Related Companies and Tools

This page (NASDAQ:SUPN) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -